Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Condition(s):Advanced Solid TumorsLast Updated:July 20, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Advanced Solid TumorsLast Updated:July 20, 2023Recruiting
Condition(s):Bladder CancerLast Updated:July 11, 2022Terminated
Condition(s):Gastrointestinal Stromal TumorsLast Updated:April 27, 2016Completed
Condition(s):Adenoid Cystic CarcinomaLast Updated:November 13, 2014Completed
Condition(s):Metastatic Clear Cell Renal CancerLast Updated:November 13, 2013Completed
Condition(s):Clear Cell Renal Cell CarcinomaLast Updated:February 3, 2015Unknown status
Condition(s):Tumor Pathway Activations Inhibited by DovitinibLast Updated:March 20, 2017Completed
Condition(s):Adrenocortical CarcinomaLast Updated:April 25, 2017Completed
Condition(s):Gastrointestinal Stromal TumorsLast Updated:August 4, 2015Withdrawn
Condition(s):Gastric CancerLast Updated:July 14, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.